Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 583

1.

IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers.

Wolf GT, Moyer JS, Kaplan MJ, Newman JG, Egan JE, Berinstein NL, Whiteside TL.

Onco Targets Ther. 2018 Jun 28;11:3731-3746. doi: 10.2147/OTT.S165411. eCollection 2018. Review.

2.

Plasma-derived Exosomes Reverse Epithelial-to-Mesenchymal Transition after Photodynamic Therapy of Patients with Head and Neck Cancer.

Theodoraki MN, Yerneni SS, Brunner C, Theodorakis J, Hoffmann TK, Whiteside TL.

Oncoscience. 2018 Apr 29;5(3-4):75-87. doi: 10.18632/oncoscience.410. eCollection 2018 Mar.

3.

Exosomes in acute myeloid leukemia inhibit hematopoiesis.

Boyiadzis M, Whiteside TL.

Curr Opin Hematol. 2018 Jul;25(4):279-284. doi: 10.1097/MOH.0000000000000439.

PMID:
29846239
4.

Microvessel density in head and neck squamous cell carcinoma.

Szafarowski T, Sierdzinski J, Szczepanski MJ, Whiteside TL, Ludwig N, Krzeski A.

Eur Arch Otorhinolaryngol. 2018 Jul;275(7):1845-1851. doi: 10.1007/s00405-018-4996-2. Epub 2018 May 10.

5.

Polyfunctionality of CD4+ T lymphocytes is increased after chemoradiotherapy of head and neck squamous cell carcinoma.

Doescher J, Jeske S, Weissinger SE, Brunner C, Laban S, Bölke E, Hoffmann TK, Whiteside TL, Schuler PJ.

Strahlenther Onkol. 2018 May;194(5):392-402. doi: 10.1007/s00066-018-1289-z. Epub 2018 Apr 16.

PMID:
29663037
6.

Lymphoma exosomes reprogram the bone marrow.

Whiteside TL.

Blood. 2018 Apr 12;131(15):1635-1636. doi: 10.1182/blood-2018-02-830497. No abstract available.

7.

Potential roles of tumor-derived exosomes in angiogenesis.

Ludwig N, Whiteside TL.

Expert Opin Ther Targets. 2018 May;22(5):409-417. doi: 10.1080/14728222.2018.1464141. Epub 2018 Apr 26.

PMID:
29634426
8.

The emerging role of plasma exosomes in diagnosis, prognosis and therapies of patients with cancer.

Whiteside TL.

Contemp Oncol (Pozn). 2018 Mar;22(1A):38-40. doi: 10.5114/wo.2018.73882. Epub 2018 Mar 5. Review.

9.

FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity.

Whiteside TL.

Expert Opin Ther Targets. 2018 Apr;22(4):353-363. doi: 10.1080/14728222.2018.1451514. Epub 2018 Apr 10.

PMID:
29532697
10.

Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma.

Sharma P, Ludwig S, Muller L, Hong CS, Kirkwood JM, Ferrone S, Whiteside TL.

J Extracell Vesicles. 2018 Feb 15;7(1):1435138. doi: 10.1080/20013078.2018.1435138. eCollection 2018.

11.

Introducing a New Series: Immunotherapy Facts and Hopes.

Melero I, Sznol M, Tessmer MS, Whiteside TL, Wolchok JD.

Clin Cancer Res. 2018 Apr 15;24(8):1773-1774. doi: 10.1158/1078-0432.CCR-18-0408. Epub 2018 Feb 23. No abstract available.

PMID:
29476022
12.

Separation of plasma-derived exosomes into CD3(+) and CD3(-) fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients.

Theodoraki MN, Hoffmann TK, Whiteside TL.

Clin Exp Immunol. 2018 Jun;192(3):271-283. doi: 10.1111/cei.13113. Epub 2018 Mar 12.

PMID:
29431869
13.

Profiling of plasma-derived extracellular vesicles cargo for diagnosis of pancreatic malignancy.

Whiteside TL.

Ann Transl Med. 2017 Dec;5(24):501. doi: 10.21037/atm.2017.10.23. No abstract available.

14.

Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment.

Whiteside TL.

Semin Immunol. 2018 Feb;35:69-79. doi: 10.1016/j.smim.2017.12.003. Epub 2017 Dec 27. Review.

PMID:
29289420
15.

Exosomes in Cancer: Another Mechanism of Tumor-Induced Immune Suppression.

Whiteside TL.

Adv Exp Med Biol. 2017;1036:81-89. doi: 10.1007/978-3-319-67577-0_6. Review.

PMID:
29275466
16.

Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients.

Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL.

Clin Cancer Res. 2018 Feb 15;24(4):896-905. doi: 10.1158/1078-0432.CCR-17-2664. Epub 2017 Dec 12.

PMID:
29233903
17.

Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.

Geskin LJ, Akilov OE, Kwon S, Schowalter M, Watkins S, Whiteside TL, Butterfield LH, Falo LD Jr.

Cancer Immunol Immunother. 2018 Mar;67(3):423-434. doi: 10.1007/s00262-017-2090-z. Epub 2017 Dec 4.

PMID:
29204699
18.

The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy.

Whiteside TL.

Future Oncol. 2017 Dec;13(28):2583-2592. doi: 10.2217/fon-2017-0343. Epub 2017 Dec 4.

PMID:
29198150
19.

Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia.

Hong CS, Sharma P, Yerneni SS, Simms P, Jackson EK, Whiteside TL, Boyiadzis M.

Sci Rep. 2017 Oct 31;7(1):14684. doi: 10.1038/s41598-017-14661-w.

20.

Human tumor-derived exosomes (TEX) regulate Treg functions via cell surface signaling rather than uptake mechanisms.

Muller L, Simms P, Hong CS, Nishimura MI, Jackson EK, Watkins SC, Whiteside TL.

Oncoimmunology. 2017 Jul 19;6(8):e1261243. doi: 10.1080/2162402X.2016.1261243. eCollection 2017.

PMID:
28919985
21.

Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.

Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou JZ, Farah R, Dorritie KA, Raptis A, Lim SH, Wang H, Lapteva N, Mei Z, Butterfield LH, Rooney CM, Whiteside TL.

Cytotherapy. 2017 Oct;19(10):1225-1232. doi: 10.1016/j.jcyt.2017.07.008. Epub 2017 Aug 30.

PMID:
28864289
22.

Response commentary: exosomes vs microvesicles in hematological malignancies.

Whiteside TL, Boyiadzis M.

Leukemia. 2017 Oct;31(10):2277. doi: 10.1038/leu.2017.248. Epub 2017 Aug 4. No abstract available.

23.

Head and Neck Carcinoma Immunotherapy: Facts and Hopes.

Whiteside TL.

Clin Cancer Res. 2018 Jan 1;24(1):6-13. doi: 10.1158/1078-0432.CCR-17-1261. Epub 2017 Jul 27. Review.

PMID:
28751445
24.

Isolation of Biologically Active Exosomes from Plasma of Patients with Cancer.

Hong CS, Funk S, Whiteside TL.

Methods Mol Biol. 2017;1633:257-265. doi: 10.1007/978-1-4939-7142-8_16.

PMID:
28735492
25.

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).

Butterfield LH, Zhao F, Lee S, Tarhini AA, Margolin KA, White RL, Atkins MB, Cohen GI, Whiteside TL, Kirkwood JM, Lawson DH.

Clin Cancer Res. 2017 Sep 1;23(17):5034-5043. doi: 10.1158/1078-0432.CCR-16-3016. Epub 2017 May 23.

PMID:
28536308
26.

Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer.

Ludwig S, Floros T, Theodoraki MN, Hong CS, Jackson EK, Lang S, Whiteside TL.

Clin Cancer Res. 2017 Aug 15;23(16):4843-4854. doi: 10.1158/1078-0432.CCR-16-2819. Epub 2017 Apr 11.

PMID:
28400428
27.

Targeting adenosine in cancer immunotherapy: a review of recent progress.

Whiteside TL.

Expert Rev Anticancer Ther. 2017 Jun;17(6):527-535. doi: 10.1080/14737140.2017.1316197. Epub 2017 Apr 27. Review.

PMID:
28399672
28.

Exosomes carrying immunoinhibitory proteins and their role in cancer.

Whiteside TL.

Clin Exp Immunol. 2017 Sep;189(3):259-267. doi: 10.1111/cei.12974. Epub 2017 May 19. Review.

PMID:
28369805
29.

The emerging roles of tumor-derived exosomes in hematological malignancies.

Boyiadzis M, Whiteside TL.

Leukemia. 2017 Jun;31(6):1259-1268. doi: 10.1038/leu.2017.91. Epub 2017 Mar 21. Review.

PMID:
28321122
30.

Extracellular vesicles isolation and their biomarker potential: are we ready for testing?

Whiteside TL.

Ann Transl Med. 2017 Feb;5(3):54. doi: 10.21037/atm.2017.01.62. No abstract available.

31.

Tumor-Derived Exosomes and Their Role in Tumor-Induced Immune Suppression.

Whiteside TL.

Vaccines (Basel). 2016 Oct 20;4(4). pii: E35. Review.

32.

Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.

Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H.

J Neurooncol. 2016 Dec;130(3):517-527. Epub 2016 Sep 13.

33.

Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.

Szajnik M, Czystowska-Kuźmicz M, Elishaev E, Whiteside TL.

Expert Rev Mol Diagn. 2016 Aug;16(8):811-26. doi: 10.1080/14737159.2016.1194758. Epub 2016 Jun 23. Review.

34.

Tumor-Derived Exosomes and Their Role in Cancer Progression.

Whiteside TL.

Adv Clin Chem. 2016;74:103-41. doi: 10.1016/bs.acc.2015.12.005. Epub 2016 Apr 7. Review.

35.

Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer.

Radomski M, Zeh HJ, Edington HD, Pingpank JF, Butterfield LH, Whiteside TL, Wieckowski E, Bartlett DL, Kalinski P.

J Immunother Cancer. 2016 Apr 19;4:24. doi: 10.1186/s40425-016-0128-y. eCollection 2016.

36.

Emerging Opportunities and Challenges in Cancer Immunotherapy.

Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I.

Clin Cancer Res. 2016 Apr 15;22(8):1845-55. doi: 10.1158/1078-0432.CCR-16-0049. Review.

37.

Phenotypic and functional characteristics of CD39high human regulatory B cells (Breg).

Figueiró F, Muller L, Funk S, Jackson EK, Battastini AM, Whiteside TL.

Oncoimmunology. 2016 Feb 26;5(2):e1082703. eCollection 2016 Feb.

38.

Plasma-derived exosomes in acute myeloid leukemia for detection of minimal residual disease: are we ready?

Boyiadzis M, Whiteside TL.

Expert Rev Mol Diagn. 2016 Jun;16(6):623-9. doi: 10.1080/14737159.2016.1174578. Epub 2016 Apr 25. Review.

39.

Isolation of biologically active and morphologically intact exosomes from plasma of patients with cancer.

Hong CS, Funk S, Muller L, Boyiadzis M, Whiteside TL.

J Extracell Vesicles. 2016 Mar 24;5:29289. doi: 10.3402/jev.v5.29289. eCollection 2016.

40.

Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.

Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H.

Neuro Oncol. 2016 Aug;18(8):1157-68. doi: 10.1093/neuonc/now026. Epub 2016 Mar 15.

41.

Exosomes and tumor-mediated immune suppression.

Whiteside TL.

J Clin Invest. 2016 Apr 1;126(4):1216-23. doi: 10.1172/JCI81136. Epub 2016 Feb 29. Review.

42.

Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells.

Zdanov S, Mandapathil M, Abu Eid R, Adamson-Fadeyi S, Wilson W, Qian J, Carnie A, Tarasova N, Mkrtichyan M, Berzofsky JA, Whiteside TL, Khleif SN.

Cancer Immunol Res. 2016 Apr;4(4):354-65. doi: 10.1158/2326-6066.CIR-15-0241. Epub 2016 Feb 15.

43.

Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets.

Muller L, Mitsuhashi M, Simms P, Gooding WE, Whiteside TL.

Sci Rep. 2016 Feb 4;6:20254. doi: 10.1038/srep20254.

44.

Novel technologies and emerging biomarkers for personalized cancer immunotherapy.

Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H, Song W, Stack EC, Wang E, Whiteside TL, Zhao Y, Zwierzina H, Butterfield LH, Fox BA.

J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016. Review.

45.

Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells.

Macatangay BJ, Riddler SA, Wheeler ND, Spindler J, Lawani M, Hong F, Buffo MJ, Whiteside TL, Kearney MF, Mellors JW, Rinaldo CR.

J Infect Dis. 2016 May 1;213(9):1400-9. doi: 10.1093/infdis/jiv582. Epub 2015 Dec 8.

46.

RE: Effect of Nasopharyngeal Carcinoma-Derived Exosomes on Human Regulatory T Cells.

Whiteside TL.

J Natl Cancer Inst. 2015 Sep 23;107(12):djv276. doi: 10.1093/jnci/djv276. Print 2015 Dec. No abstract available.

PMID:
26405093
48.

The potential of tumor-derived exosomes for noninvasive cancer monitoring.

Whiteside TL.

Expert Rev Mol Diagn. 2015;15(10):1293-310. doi: 10.1586/14737159.2015.1071666. Epub 2015 Aug 2. Review.

49.

Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival.

Muller L, Muller-Haegele S, Mitsuhashi M, Gooding W, Okada H, Whiteside TL.

Oncoimmunology. 2015 Mar 2;4(6):e1008347. eCollection 2015 Jun.

50.

Immunotherapy for acute leukemia.

Boyiadzis M, Whiteside TL, Pavletic SZ.

Aging (Albany NY). 2015 Jun;7(6):354-5. No abstract available.

Supplemental Content

Loading ...
Support Center